Imeka is the only company offering a non invasive technology to help understand neuroinflammation in white matter.

Using our technology improves patient adherence to trials and renders the trial simpler and more comfortable.

With Imeka's technology you have

- Better recruitment
- Increased patient retention
- Simpler logistics
- Less expensive
- Better patient experience

Illustration of the patient's journey when participating in a study for Alzheimer. With Imeka only an MRI procedure. With standard procedures, the patient has to go through a lumbar puncture plus an MRI.

Invasive procedures like PET & Spinal Tap have an impact on patient willingness to participate in a clinical trial.

Imeka’s non-invasive technology adds a positive value to patient’s desire to participate in a clinical trial.

Furthermore, diffusion MRI can generate AFD (Apparent Fiber Density) markers that correlate negatively with NFL (Neurofilament light), enabling a more precise tracking of patient’s changes, without needing biological samples.

Improve subject selection by tracking through white matter hyperintensity lesions. This helps with assessing if structure is left or not.

Another improvement for your trials:

Bundle segmentation enables better drug targeting in specific white matter areas. This is better and more specific than whole brain measures.

The role of White Matter in Alzheimer Disease.

Free-water is a localized proxy sensitive to neuroinflammation which can be used for better drug selection and drug effect assessment. This proxy correlates with Beta Amyloid PET gold standard.

Free-water imaging based on diffusion MRI  is a fast and cost-effective method that can help understand neuroinflammation and is available today.

View Maxime Descoteaux’s webinar on diffusion MRI and Free-water.

Imeka’s expertise in free-water imaging lead to a collaboration with Pfizer, a project that became the subject of an abstract at the 2018 ISMRM conference.
See article published in Frontiers

“This study demonstrates that after removing partial volume contamination as well as WMHs lesions, the free water content of healthy looking white matter differentiates MCI and AD groups from healthy subjects. Our method is based on existing DTI-like diffusion data, is atlas free, requires no registration with a reference brain, no PET scan, no tractography, has few tunable parameters, and takes a few minutes only of computation.

The method is a simple but powerful approach that may be used in the context of patient selection and stratification for novel treatments that are aimed at treating or preventing inflammation components of AD using legacy or standard diffusion MRI data. The significant differences of our FW metrics between NC and MCI as well as NC and AD may demonstrate the potential of FW as a tool to study neuroinflammation. We intend to extend this work with analyses of FW metrics in specific white matter bundles and sections of bundles. Also, characterization over time of our new FW metrics in an MCI population could help differentiate those older adults who will remain relatively stable and those who will progress to AD, which has utility for patient selection and stratification of subjects in preclinical stages of AD.”

Our publications related to Alzheimer's disease